New agreement with Pfizer to identify novel targets for cancer therapy
The University of Melbourne will partner with one of the world's leading biopharmaceutical companies, Pfizer, to identify and validate new targets for cancer treatment.
The new agreement will provide support to immunity mechanisms research led by Associate Professor Laura Mackay from the Peter Doherty Institute (PDI), Department of Immunology & Microbiology, in the School of Biomedical Sciences.
Associate Professor Mackay said it is increasingly apparent that immune cells are the key to developing better oncology treatments.
“This research project will enable development of therapies to target tissue-resident lymphocytes that are key players for cancer control.” Associate Professor Mackay said.
View the full article here, originally published by PDI on 23 September.